Acute hematogenous osteomyelitis and septic arthritis in children.
This retrospective study analyzed the clinical, bacteriological, and radiological features of pediatric patients with acute hematogenous osteomyelitis and septic arthritis. Eighty-four patients with septic arthritis and 39 with acute hematogenous osteomyelitis were enrolled. Their age ranged from 13 days to 17 years. In patients with septic arthritis, the hip joint was the most often infected site. The tibia was the most often involved site in acute hematogenous osteomyelitis. A bacteriological diagnosis was established in 78 (63%) patients. Overall, methicillin-susceptible Staphylococcus aureus (36 cases) was the most common causative organism identified, followed by methicillin-resistant S. aureus (10 cases). The median duration of antibiotic therapy was 33 days. Serum bactericidal titers were obtained for 19 (15%) of the 123 patients. The median duration of hospitalization and antibiotic treatment was not significantly different between patients with and without serum bactericidal titer testing. More patients without serum bactericidal titer testing had symptom relapse which required re-admission for further treatment. In conclusion, the incidence of methicillin-resistant S. aureus as a cause of bone and joint infections has been increasing. Serum bactericidal titer is valuable for the management of patients receiving sequential therapy for acute hematogenous osteomyelitis and septic arthritis.
Kao
Hui-Chin
HC
Department of Pediatrics, Li-Shin Hospital, Taiwan, ROC.
Huang
Yhu-Chering
YC
Chiu
Cheng-Hsun
CH
Chang
Luan-Yin
LY
Lee
Zhon-Liau
ZL
Chung
Pei-Wen
PW
Kao
Feng-Chen
FC
Lin
Tzou-Yien
TY
D000208:Acute Disease; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D001424:Bacterial Infections / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D001770:Blood Bactericidal Activity; D002648:Child; D002675:Child, Preschool; D005260:Female; D006621:Hip Joint / Q000382:microbiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007719:Knee Joint / Q000382:microbiology; D008297:Male; D008712:Methicillin / Q000627:therapeutic use; D016106:Methicillin Resistance; D010019:Osteomyelitis / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D012189:Retrospective Studies; D013977:Tibia / Q000382:microbiology / Q000473:pathology
D000900:Anti-Bacterial Agents; D008712:Methicillin